Access, Greek sites, regulatory developments and Greek research participation — only when genuinely relevant.
Studies with verified Greek centres
REMASTER: remibrutinib is being studied in secondary progressive MS
Large study to confirm benefit and safety
EU register: seven named Greek centres (checked 25 October); ClinicalTrials.gov: six Greek location rows under generic site labels (update posted 13 October). No one-to-one match established. The EU register reported recruiting for Greece as a country at its 25 Oct 2026 check. Confirm current enrolment and eligibility with a centre; a country status does not confirm that every listed centre is enrolling.
Orelabrutinib: Phase 3 studies in two forms of progressive MS
Large study to confirm benefit and safety
CTIS checks: PriMroSe (25 October 2026) — Greece accepting participants, seven Greek site listings; Monarch (28 October 2026; Greek entry last updated 16 October) — Greece recruitment pending, six Greek site listings. CTIS shows no site-specific recruitment status for either study. The ClinicalTrials.gov records, both updated 27 October 2026, list no Greek location for PriMroSe and one for Monarch: "Errikos Dunant Hospital", Athens, listed as accepting participants, which matches the Henry Dunant Hospital Center in the CTIS list. Confirm current enrolment and eligibility with the relevant centre; no listed centre is guaranteed to be enrolling.
Each is recorded separately with country, date and source. FDA action does not equal EU approval; EU approval does not confirm Greek availability or reimbursement.
Application submitted
Scientific or regulatory opinion
Marketing authorisation for a specific indication
Commercial availability in Greece
Reimbursement in Greece
Access through a named recruiting trial site
If you are considering a trial from Greece
This is a practical route to verify access; it is not a recommendation to join a study.
1. Open the official recordUse ClinicalTrials.gov or CTIS, rather than a news item or social post.
2. Check location and eligibilityConfirm the country and named site, recruitment status, contact details and inclusion criteria.
3. Discuss it with your care teamA neurologist can help put eligibility, potential burden, standard treatment and safety in context. The study site makes the final eligibility decision.
Selected developments outside Greece
These dated reports do not establish a current place in a Greek centre. Check the linked primary source and contact the study team for current availability.
EUROPEAN ACCESS
ACT-1004-1239: European Phase 2 study; Greece not listed
Netherlands accepting participants at country level; Greece not listedPhase 2 study in people; benefit not established
This card retains its 16 September 2026 date. At the 25 October 2026 source check, the official EU CTIS record listed the Netherlands as the only country, with recruitment ongoing there; Greece was not listed. Country-level recruitment does not establish enrolment or available places at an individual centre.
What this means for people with MS
This is a research study, not proven benefit or a confirmed recruitment option in Greece. Check eligibility and current centre availability with the sponsor or study team before considering participation.
How reliable is this source?: Official EU CTIS country status checked 25 October 2026; the earlier independent CTIS.eu mirror remains a historical location lead
OCTOPUS: alpha-lipoic acid advances; metformin arm stops
UK platform; interim decision on 17 September 2026Study in people; interim MRI and clinical signal, not definitive benefit
On 17 September 2026, the OCTOPUS trial team announced that alpha-lipoic acid would advance to Stage 2 after an interim MRI and clinical signal; the metformin arm would stop. At that announcement, UK residents with primary or secondary progressive MS could register interest in Stage 2. The announcement does not identify a Greek centre accepting participants.
What this means for people with MS
The interim decision is a reason for further study, not proof that alpha-lipoic acid benefits people with progressive MS. It does not support metformin benefit in this trial or establish a treatment available in Greece.
How reliable is this source?: Official OCTOPUS / UCL trial-team decision
New Fleming/NKUA study examines fibronectin and failed myelin repair
Laboratory or animal research; not a treatment for patientsPeer-reviewed PNAS; cells and animal models
Researchers including teams from BSRC Alexander Fleming and the National and Kapodistrian University of Athens described a mechanism in which fibronectin accumulation may trap myelin-forming precursor cells (OPCs) in demyelinated lesions. Fibronectin inhibition improved remyelination in experimental models.
What this means for people with MS
This is important Greek participation in basic and translational research, not an available treatment or human trial. There is no evidence of benefit to patients in people.
How reliable is this source?: High for a laboratory or animal research finding • peer-reviewed primary paper
